6.04 USD
-0.07 (-1.15%)
6.04 USD
0 (0%)
We assign a fundamental rating of 3 out of 10 to MYGN. MYGN was compared to 528 industry peers in the Biotechnology industry. MYGN may be in some trouble as it scores bad on both profitability and health. MYGN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- MYGN had positive earnings in the past year.
- MYGN had a negative operating cash flow in the past year.
- In the past 5 years MYGN always reported negative net income.
- In multiple years MYGN reported negative operating cash flow during the last 5 years.
1.2 Ratios
- With a Return On Assets value of -55.01%, MYGN perfoms like the industry average, outperforming 45.64% of the companies in the same industry.
- Looking at the Return On Equity, with a value of -107.43%, MYGN is in line with its industry, outperforming 43.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -55.01% | ||
| ROE | -107.43% | ||
| ROIC | N/A |
ROA(3y)-14.9%
ROA(5y)-12.19%
ROE(3y)-21.47%
ROE(5y)-17.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Gross Margin value of 70.36%, MYGN belongs to the best of the industry, outperforming 81.63% of the companies in the same industry.
- MYGN's Gross Margin has declined in the last couple of years.
- The Profit Margin and Operating Margin are not available for MYGN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.36% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-1.76%
2. Health
2.1 Basic Checks
- MYGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
- MYGN has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, MYGN has more shares outstanding
- Compared to 1 year ago, MYGN has a worse debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -0.11, we must say that MYGN is in the distress zone and has some risk of bankruptcy.
- MYGN has a Altman-Z score (-0.11) which is comparable to the rest of the industry.
- MYGN has a Debt/Equity ratio of 0.32. This is a healthy value indicating a solid balance between debt and equity.
- MYGN's Debt to Equity ratio of 0.32 is on the low side compared to the rest of the industry. MYGN is outperformed by 68.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.32 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.11 |
ROIC/WACCN/A
WACC8.47%
2.3 Liquidity
- A Current Ratio of 2.33 indicates that MYGN has no problem at all paying its short term obligations.
- MYGN has a Current ratio of 2.33. This is in the lower half of the industry: MYGN underperforms 71.97% of its industry peers.
- A Quick Ratio of 2.12 indicates that MYGN has no problem at all paying its short term obligations.
- MYGN's Quick ratio of 2.12 is on the low side compared to the rest of the industry. MYGN is outperformed by 72.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.33 | ||
| Quick Ratio | 2.12 |
3. Growth
3.1 Past
- The earnings per share for MYGN have decreased strongly by -64.29% in the last year.
- MYGN shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 86.63% yearly.
- MYGN shows a small growth in Revenue. In the last year, the Revenue has grown by 0.21%.
- Measured over the past years, MYGN shows a decrease in Revenue. The Revenue has been decreasing by -0.32% on average per year.
EPS 1Y (TTM)-64.29%
EPS 3Y86.63%
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)0.21%
Revenue growth 3Y6.64%
Revenue growth 5Y-0.32%
Sales Q2Q%-3.56%
3.2 Future
- The Earnings Per Share is expected to grow by 19.84% on average over the next years. This is quite good.
- The Revenue is expected to grow by 3.31% on average over the next years.
EPS Next Y-93.22%
EPS Next 2Y-25.72%
EPS Next 3Y10.72%
EPS Next 5Y19.84%
Revenue Next Year-2.08%
Revenue Next 2Y1.58%
Revenue Next 3Y2.85%
Revenue Next 5Y3.31%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 120.80, MYGN can be considered very expensive at the moment.
- 89.39% of the companies in the same industry are more expensive than MYGN, based on the Price/Earnings ratio.
- The average S&P500 Price/Earnings ratio is at 27.54. MYGN is valued rather expensively when compared to this.
- With a Price/Forward Earnings ratio of 84.20, MYGN can be considered very expensive at the moment.
- Based on the Price/Forward Earnings ratio, MYGN is valued cheaper than 88.45% of the companies in the same industry.
- MYGN's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.31.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 120.8 | ||
| Fwd PE | 84.2 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-25.72%
EPS Next 3Y10.72%
5. Dividend
5.1 Amount
- MYGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
6.04
-0.07 (-1.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-15 2026-01-15/amc
Earnings (Next)05-04 2026-05-04/amc
Inst Owners98.58%
Inst Owner Change-0.18%
Ins Owners2.58%
Ins Owner Change0.27%
Market Cap562.99M
Revenue(TTM)825.30M
Net Income(TTM)-400.50M
Analysts53.33
Price Target7.85 (29.97%)
Short Float %9.57%
Short Ratio7.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)363.83%
Min EPS beat(2)100%
Max EPS beat(2)627.66%
EPS beat(4)3
Avg EPS beat(4)193.66%
Min EPS beat(4)-2.9%
Max EPS beat(4)627.66%
EPS beat(8)7
Avg EPS beat(8)222.43%
EPS beat(12)10
Avg EPS beat(12)156.03%
EPS beat(16)13
Avg EPS beat(16)126.64%
Revenue beat(2)1
Avg Revenue beat(2)0.96%
Min Revenue beat(2)-1.57%
Max Revenue beat(2)3.49%
Revenue beat(4)1
Avg Revenue beat(4)-1.19%
Min Revenue beat(4)-4.24%
Max Revenue beat(4)3.49%
Revenue beat(8)3
Avg Revenue beat(8)-0.37%
Revenue beat(12)6
Avg Revenue beat(12)0.38%
Revenue beat(16)8
Avg Revenue beat(16)-0.17%
PT rev (1m)0%
PT rev (3m)12.51%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-462.33%
EPS NY rev (1m)0%
EPS NY rev (3m)40.49%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.48%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)-0.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 120.8 | ||
| Fwd PE | 84.2 | ||
| P/S | 0.68 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.51 | ||
| P/tB | 3.56 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.05
EY0.83%
EPS(NY)0.07
Fwd EY1.19%
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS8.85
BVpS4
TBVpS1.7
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.12
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -55.01% | ||
| ROE | -107.43% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.36% | ||
| FCFM | N/A |
ROA(3y)-14.9%
ROA(5y)-12.19%
ROE(3y)-21.47%
ROE(5y)-17.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-1.76%
F-Score5
Asset Turnover1.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.32 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 48.14% | ||
| Cap/Sales | 3.28% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.33 | ||
| Quick Ratio | 2.12 | ||
| Altman-Z | -0.11 |
F-Score5
WACC8.47%
ROIC/WACCN/A
Cap/Depr(3y)84.3%
Cap/Depr(5y)59.15%
Cap/Sales(3y)6.65%
Cap/Sales(5y)4.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-64.29%
EPS 3Y86.63%
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y-93.22%
EPS Next 2Y-25.72%
EPS Next 3Y10.72%
EPS Next 5Y19.84%
Revenue 1Y (TTM)0.21%
Revenue growth 3Y6.64%
Revenue growth 5Y-0.32%
Sales Q2Q%-3.56%
Revenue Next Year-2.08%
Revenue Next 2Y1.58%
Revenue Next 3Y2.85%
Revenue Next 5Y3.31%
EBIT growth 1Y13.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.3%
EBIT Next 3Y32.16%
EBIT Next 5Y15.6%
FCF growth 1Y78.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y96.09%
OCF growth 3YN/A
OCF growth 5YN/A
MYRIAD GENETICS INC / MYGN FAQ
What is the ChartMill fundamental rating of MYRIAD GENETICS INC (MYGN) stock?
ChartMill assigns a fundamental rating of 3 / 10 to MYGN.
What is the valuation status of MYRIAD GENETICS INC (MYGN) stock?
ChartMill assigns a valuation rating of 2 / 10 to MYRIAD GENETICS INC (MYGN). This can be considered as Overvalued.
How profitable is MYRIAD GENETICS INC (MYGN) stock?
MYRIAD GENETICS INC (MYGN) has a profitability rating of 2 / 10.
Can you provide the financial health for MYGN stock?
The financial health rating of MYRIAD GENETICS INC (MYGN) is 3 / 10.